Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types
Phase of Trial: Phase II
Latest Information Update: 25 May 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Germ cell and embryonal neoplasms; Neuroendocrine tumours; Ovarian cancer; Sarcoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms AcSe
- Sponsors UNICANCER
- 15 May 2018 Planned number of patients changed from 300 to 350.
- 05 Sep 2017 Status changed from not yet recruiting to recruiting.
- 03 May 2017 Planned initiation date changed from 1 Feb 2017 to 1 Jun 2017.